Dawmed Systems Share Discussion Threads

[serious punter] 03/2/2005 08:28

Mornin All

Good start to the day, up already 17/21. IMHO, they've now got an opportunity to print money, getting preferred supplier status is a huge door opener.

[r0ger moore] 02/2/2005 20:35

in the next few months i will kick back and watch the rns fly in easy money

[serious punter] 02/2/2005 15:25

Just ticked up 16/20

[serious punter] 02/2/2005 12:47

mjcrockett

I thought that there might be an hours delay, but eventually the trade will show. MMs not wanting to do much business today with a strip spread of 5p.

Online via IG DMA 15.25/18.75

[mjcrockett] 02/2/2005 12:02

SP Welcome - it seems anything over 3k takes 2 hours to show.

Biomax, I use Jarvis for T+ trades. They are £9.50 to trade online and go up to T+20. They are very good, except they charge £15 to withraw cash from your account. If you are interested go to
MJ

[serious punter] 02/2/2005 11:30

Just joined the club with 10k - not showing yet.

[biomax] 02/2/2005 11:21

thanks, barclays doesn't do T pluses. I uses TDW mainly. Do you know any online broker which does T plus 10 or longer?

[mjcrockett] 02/2/2005 11:00

Barclays. Between my wife and I, we have 5 different brokers all with online dealing. We find that the prices we get from Barclays are rarely beaten by the other 4.

I have just tried a quote from my TD Waterhouse account and they now offer DSY at 18.5.


MJ

[biomax] 02/2/2005 10:07

which brokers is that, TDW quotes 19

[mjcrockett] 02/2/2005 09:48

Biomax, this spread is so silly. The current spread is 4p - 15/19. However, a quote from my broker gives the actual price to deal at as 15.75/17.75 - a spread of 2, which is much more acceptable. If the MM's quoted DSY with a spread of 2 it would sell like hot cakes - perhaps they don't want that.

MJ

[biomax] 02/2/2005 09:38

interesting co, with 200 NHS trust in the UK, and size of an aveage contact could be upto 1 mln, the potential revenue could be as high as 200-100 mln,

market cap now is 3 mln, the only problem is a bid spread

[mjcrockett] 02/2/2005 08:49

Excellent news again this morning from Dawmed further underlying the potential here. It will be interesting to see how much buying this attracts today.

MJ

[r0ger moore] 31/1/2005 18:31

cant you report market makers nowadays the spread is a disgrace very good future for this company if the spread was not so tight this would be the front runner in my portfolio

[dr knowledge] 31/1/2005 16:19

mjcrockett - so right! The spread is a killer - agree with you though on the prospects based on mkt cap!

[leeaadvfn] 31/1/2005 15:15

I've been watching these for a while too

£1m order for a £3.5m mkt cap company sounds very promising

Looks like some fun to come so decided to have a small dabble (15.75p this afternoon)

-good luck

[mjcrockett] 31/1/2005 10:46

I have made my first purchase of Dawmed shares today at 14.5p. This was after getting a quote from another broker at 17p - it pays to shop around. I have had Dawmed on my watchlist for over 2 years and today's announcement finally convinced me that it was worth a dabble. The shares seem very lowly rated - this must be partly due to the stupid spread. I am sure if these had opened today at 13/15 lots more people would have bought.

MJ

[dr knowledge] 31/1/2005 09:29

Bullish broker note released today - comments on £1m value of recent orders and re-iterates "BUY" recommendation (Daniel Stewart) - very quiet here!!!

[tenapen] 26/12/2004 11:23

Merry Christmas to all Damned Share holders,
I own some (kind of) through a VCT and have had a eye on them for a few months now. I feel they are a buy but i do not see a need to rush in and buy but to wait for the RNS to start to flow.
kenny.

[ishwar] 24/12/2004 12:30

very small volumes

[theophilus] 21/12/2004 16:15

Just a brief extract from the results above.

More details below as posted on advfn


DAWMED SYSTEMS PLC

PRELIMINARY RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2004

The Board of DawMed Systems plc ("DawMed" or "the Company"), the medical
devices company which designs, manufactures, sells and services washer
disinfectors used by NHS Trust hospitals, private hospitals and clinics,
today announces results for the year ended 30 September 2004.

Key Points

*Turnover up by 4.2% to #4.71m (2003: #4.53m)

*Net loss of #403,000

*Sales for Wassenburg flexible endoscope Washer Disinfector products
("WD") up 44.6%

*Turnover up 38.5% in Support Services Division

*31.4% increase in gross profit to #1.79m

*Shareholders' funds at #844,000

*Clinic in full production, with more than 15 sold since July

Commenting on today's announcement, Kevin Gilmore, Chairman of DawMed, said:
"I am pleased to report that every Division of your Company is indicating
significantly improved levels of business compared with 2004, which I anticipate
will lead to a return to profitability this year. Your Company continues to
focus on the current and future growth areas, namely Wassenburg flexible
endoscope WD products, the Support Services Division and the Clinic bench top
WDD. These three important areas are seen by the Board as the key drivers to the
future growth and profitability of the business, on which it intends to
concentrate the Company's resources.

"The focus is now on achieving a good return on the past investments, aided by
only modest increases in overheads, which will be strictly related to increases
in turnover, due to the adequacy of the now well established organisation and
infrastructure."

Chairman's Statement :

On behalf of the Board, I am pleased to announce that, at the year ended 30
September 2004, your Company's performance was in line with the Directors'
expectations, showing a modest increase in overall sales performance over the
previous year.

During the period, overall turnover increased by 4.2% to #4.71m (2003: #4.53m).
Particularly pleasing was the strong growth achieved by the Wassenburg flexible
endoscope Washer Disinfector products ("WD"), with sales increasing by 44.6%,
like-for-like and the turnover in our Support Services Division which showed an
impressive 38.5% increase, compared with the previous year.

The resultant overall effect was a 31.4% increase in gross profit to #1.79m, and
an eight point increase in the gross margin percentage. Sales of the Company's
traditional large Washer Disinfector Dryer ("WDD") products were down some 55% -
a trend continuing on from the first-half of the year and foreshadowed in my
June Interim Report.

As highlighted at the time of the Interim Report, there were a large number of
third-party design delays that postponed the full launch of the new Clinic bench
top WDD until June 2004. These delays meant that sales of the Clinic to the
Primary Care market were minimal. However, I can now report that the Clinic is
in full production, and more than 15 have been sold since July. Initial feedback
has been positive and sales are in-line with revised management expectations
following the delays. As sales volumes grow, the Board is confident of the
success of this product for the year to 30 September 2005 and beyond.

According to reliable information received, I am pleased to report that NHS
spending on WDDs in the Primary Care Sector is scheduled for strong growth, as
the UK Government and the EU look to extend Secondary Healthcare decontamination
standards to the Primary Healthcare Sector. Automated WDDs offer certainty of
disinfection against the uncertainty and unlikelihood of the manual alternative
and Directors believe that it has the most functionally rich and
standards-compliant offering with the Clinic bench top WDD.

The resultant net loss of #403,000, pre and post-tax for the year, showed a
marginal decrease in the second half of the year and compares with a #293,000
loss in the previous year. Overhead spend of #2.15m showed a 31.2% increase over
the prior year, of which more than half was in respect of the infrastructure set
up exclusively for the Clinic.

At the year-end, shareholders' funds were #844,000, an increase of #110,000 over
the previous period, resulting from the new shares issued to raise #540,000
before expenses in December 2003.

Products and Services

Your Company continues to focus on the current and future growth areas, namely
Wassenburg flexible endoscope WD products, the Support Services Division and the
Clinic bench top WDD. These three important areas are seen by the Board as the
key drivers to the future growth and profitability of the business, on which it
intends to concentrate the Company's resources.

The Company is working closely with Wassenburg to further develop the UK market
for existing products and also for the introduction of exciting additions to the
product range to be made during the current financial year.

Whilst the overhead spend on the Support Services Division has increased, it was
at a much reduced rate and was an investment justified by the 100% increase in
the gross margin amount from this business Division over that achieved in the
previous year.

The Clinic bench top WDD was a joint major factor contributing to the Company's
year-end losses. With negligible sales and the resultant lack of gross margin
until the last quarter of the year, together with a full year's related
infrastructure costs incurred, the delay in availability of the product resulted
in a substantial shortfall in sales and consequentially in profitability. In the
opinion of the Directors, the product is a world market leader in terms of
design, functionality, application and compliance with the world's highest
standards and will form a key element in the Company's progress for many years.

As a consequence of the serious decline in the sales performance of the
traditional large WDD products business, the gross margin amount was half of
that achieved in the previous year and was also a joint major factor
contributing to the Company's year end losses. The current overhead spend and
the level of working capital required in this Division is being carefully
monitored.

Outlook and Future Prospects

The Directors are continually evaluating the constituent parts of the Company's
business and are pleased to report that every Division of the Company is
indicating significantly improved levels of business compared with 2004, which
the Directors anticipate will lead to a return to profitability at year end
September 2005.

Prospects for the traditional large WDD products Division in the current year to
30 September 2005 are encouraging, with the Company well placed to significantly
improve upon its 2004 performance. Nevertheless, your Board will continue to
explore alternative initiatives in this Division to improve its medium term
growth potential.

Demand for the Wassenburg flexible endoscope WD products continues to grow
satisfactorily and, with new additions to the range, it is expected that this
Division will continue to provide further growth potential in machine sales and
continuous consumables revenue this year as well as retain, in the Director's
opinion, its market leader position.

The Directors believe that the most important Division, with by far the greatest
future growth prospects for the current year and the long term future, is the
Clinic bench top WDD. The introduction during 2005 of the new compliance
requirements in the UK Primary Care market to match those already established in
the Secondary Care market is anticipated to generate further growth in UK direct
and indirect sales to dentists, general practitioners and other Primary Care
practitioners. The Company is also awaiting confirmation of its preferred
supplier status for Primary Care bench top WDDs in England, in addition to that
recently awarded to the Company by Scottish Healthcare Supplies for the Primary
Care market in Scotland. Furthermore, discussions are currently taking place
with a number of multi-national companies concerning the exciting potential of
substantial sales worldwide.

The Support Services Division should continue to benefit from the substantial
year-on-year increases in the size of the installed base of the Company's total
range of decontamination equipment, including the additional support services
associated with high potential sales of the Clinic in the UK, Europe and
Worldwide, and also from the ever more stringent compliance with standards
requirements being implemented by UK Trust Hospitals in respect of new and
existing WDD equipment. In addition, the newly initiated training function
within this Division is proving to be successful, particularly with regard to
the Wassenburg flexible endoscope WD products.

Although the Company's policy is to continuously improve its products and
services, it is not considered to be necessary to embark upon any costly new
product initiatives in the foreseeable future such as have been necessary over
recent years to arrive at our current exciting position. The focus is now on
achieving a good return on the past investments, aided by only modest increases
in overheads, which will be strictly related to increases in turnover, due to
the adequacy of the now well established organisation and infrastructure.

Kevin M Gilmore
Executive Chairman

Cheers

Th

[theophilus] 21/12/2004 16:13

PRELIMINARY RESULTS FOR THE YEAR ENDED 30 SEPTEMBER 2004

The Board of DawMed Systems plc ("DawMed" or "the Company"), the medical
devices company which designs, manufactures, sells and services washer
disinfectors used by NHS Trust hospitals, private hospitals and clinics,
today announces results for the year ended 30 September 2004.

Key Points

*Turnover up by 4.2% to #4.71m (2003: #4.53m)

*Net loss of #403,000

*Sales for Wassenburg flexible endoscope Washer Disinfector products
("WD") up 44.6%

*Turnover up 38.5% in Support Services Division

*31.4% increase in gross profit to #1.79m

*Shareholders' funds at #844,000

*Clinic in full production, with more than 15 sold since July

[r0ger moore] 19/12/2004 20:28

still no news but these are the shares you should buy a share the market ignores therefore a slow slip in share price pick em up cheap and when the news comes and people notice boom.but untill then lets all go back to sleep